Collectively, this study identifies that LYRM2 as a novel oncogenic protein in HCC and elucidates its contribution to HCC progression through enhancing HIF‐1α‐dependent glucose metabolic reprogramming. This evidence concerns the gene HIF1A and hepatocellular carcinoma.